Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$28.68 USD
-0.29 (-1.00%)
Updated Jun 12, 2024 04:00 PM ET
After-Market: $28.67 -0.01 (-0.03%) 4:38 PM ET
3-Hold of 5 3
A Value B Growth B Momentum A VGM
Brokerage Reports
Pacira BioSciences, Inc. [PCRX]
Reports for Purchase
Showing records 621 - 640 ( 721 total )
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
January and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
November Symphony Health Data for EXPAREL Released Early Due to Holiday
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
November Symphony Health Data for EXPAREL Released Early Due to Holiday; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Dec. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Potential Approval of Additional EXPAREL Manufacturing Facility Anticipated in Early April 2014
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Potential Approval of Additional EXPAREL Manufacturing Facility Anticipated in Early April 2014; Reiterate OUTPERFORM and $59 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
December 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
October Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $59 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
November and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
Q3 EXPAREL Sales Slightly Beat on Increased Traction in Orthopedics and iTAPs; Reiterate OUTPERFORM & $59 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
September Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $59 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
October and Remaining 2013 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Partnership with CrossLink Likely to Accelerate Utilization Among Orthopedics, in Our View; Reiterate OUTPERFORM and Moving to $59 12-Month PT
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
August Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $43 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
New Data Evaluating EXPAREL in Knee Surgery Demonstrates Medical and Economic Advantages Over Standard of Care; Reiterate OUTPERFORM and $43 FV
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept. 9
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Pacira BioSciences, Inc.
Industry: Medical - Drugs
July Symphony Health Data for EXPAREL; Reiterate OUTPERFORM and $43 Fair Value
Provider: WEDBUSH SECURITIES INC.
Analyst: LAU R